A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III
Latest Information Update: 24 May 2024
At a glance
- Drugs BDB 001 Beijing Defengrei Biotechnology (Primary)
- Indications Acute lung injury; COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 20 May 2024 Status changed from active, no longer recruiting to discontinued.
- 27 Dec 2023 Planned End Date changed from 7 Aug 2022 to 1 May 2024.
- 27 Dec 2023 Planned primary completion date changed from 1 Jan 2022 to 1 May 2024.